Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer

World Journal of Clinical Oncology

Volumn 5, Issue 3, 2014, Pages 248-262

  Zhao, Meng ^a   Ramaswamy, Bhuvaneswari ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Breast cancer; Endocrine resistance; Endocrine therapy; Targeted therapy; Therapeutic advances

Indexed keywords

EID: 84930194299     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v5.i3.248     Document Type: Review

References (94)

1. Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 1998; 90: 814-823 [PMID: 9625169 DOI: 10.1093/jnci/90.11.814]
2. McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science 2002; 296: 1642-1644 [PMID: 12040178 DOI: 10.1126/science.1071884]
3. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9: 631-643 [PMID: 19701242 DOI: 10.1038/nrc2713]
4. Clark GM, Osborne CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 1984; 2: 1102-1109 [PMID: 6491696]
5. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98: 1802-1810 [PMID: 14584060 DOI: 10.1002/cncr.11745]
6. Coates AS, Keshaviah A, Thörlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25: 486-492 [PMID: 17200148 DOI: 10.1200/JCO.2006.08.8617]
7. Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thörlimann B. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: The BIG 1-98 randomised clinical trial at 81 years median follow-up. Lancet Oncol 2011; 12: 1101-1108 [PMID: 22018631 DOI: 10.1016/S1470-2045(11)70270-4]
8. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011; 62: 233-247 [PMID: 20887199 DOI: 10.1146/annurev-med-070909-182917]
9. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: A southwest oncology group study. Clin Cancer Res 2004; 10: 5670-5676 [PMID: 15355892 DOI: 10.1158/1078-0432.CCR-04-0110]
10. Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008; 29: 217-233 [PMID: 18216219 DOI: 10.1210/er.2006-0045]
11. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365: 1687-1717 [PMID: 15894097 DOI: 10.1016/S0140-6736(05)66544-0]
12. Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J, Paridaens R, van de Velde CJ, Lønning PE, Morden J, Reise J, Cisar L, Menschik T, Coombes RC. Disease-related outcomes with long-Term follow-up: An updated analysis of the intergroup exemestane study. J Clin Oncol 2012; 30: 709-717 [PMID: 22042946 DOI: 10.1200/JCO.2010.33.7899]
13. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752 [PMID: 10963602 DOI: 10.1038/35021093]
14. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70 [PMID: 23000897 DOI: 10.1038/nature11412]
15. Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM, Nicholson RI. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 2006; 96: 131-146 [PMID: 16261397 DOI: 10.1007/s10549-005-9070-2]
16. Creighton CJ. The molecular profile of luminal B breast cancer. Biologics 2012; 6: 289-297 [PMID: 22956860 DOI: 10.2147/BTT.S29923]
17. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005; 23: 7721-7735 [PMID: 16234531 DOI: 10.1200/JCO.2005.09.004]
18. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010; 28: 3784-3796 [PMID: 20625130 DOI: 10.1200/JCO.2009.26.3756]
19. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-Activated protein kinase. J Clin Oncol 2005; 23: 2469-2476 [PMID: 15753463 DOI: 10.1200/JCO.2005.01.172]
20. Koch L. Pharmacotherapy: Small-molecule disruptors of glucokinase inhibition. Nat Rev Endocrinol 2014; 10: 66 [PMID: 24275740 DOI: 10.1038/nrendo.2013.244]
21. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002; 2: 101-112 [PMID: 12635173 DOI: 10.1038/nrc721]
22. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010; 70: 2085-2094 [PMID: 20179196 DOI: 10.1158/0008-5472. CAN-09-3746]
23. Miller TW, Hennessy BT, González-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, García-Echeverría C, Shyr Y, Arteaga CL. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010; 120: 2406-2413 [PMID: 20530877 DOI: 10.1172/JCI41680]
24. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 2011; 29: 4452-4461 [PMID: 22010023 DOI: 10.1200/JCO.2010.34.4879]
25. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-1657 [PMID: 12040186 DOI: 10.1126/science. 296.5573.1655]
26. Majumder S, Jacob ST. Emerging role of microRNAs in drug-resistant breast cancer. Gene Expr 2011; 15: 141-151 [PMID: 22268296 DOI: 10.3727/105221611X13176664479287]
27. Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 2009; 9: 576-586 [PMID: 19629072 DOI: 10.1038/nrc2683]
28. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 2004; 64: 1522-1533 [PMID: 14973112 DOI: 10.1158/0008-5472.CAN-03-3326]
29. Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 2001; 29: 2905-2919 [PMID: 11452016 DOI: 10.1093/nar/29.14.2905]
30. Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, Moore DH, Eppenberger U, Eppenberger-Castori S, Benz CC. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 2007; 7: [PMID: 17407600 DOI: 10.1186/1471-2407-7-59]
31. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. Pathways to tamoxifen resistance. Cancer Lett 2007; 256: 1-24 [PMID: 17475399 DOI: 10.1016/j.canlet.2007.03.016]
32. Herynk MH, Fuqua SA. Estrogen receptor mutations in human disease. Endocr Rev 2004; 25: 869-898 [PMID: 15583021 DOI: 10.1210/er.2003-0010]
33. Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Lee AV. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 2008; 26: 4078-4085 [PMID: 18757322 DOI: 10.1200/JCO.2007.13.4429]
34. Osborne CK, Schiff R. Growth factor receptor cross-Talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast 2003; 12: 362-367 [PMID: 14659106 DOI: 10.1016/S0960-9776(03)00137-1]
35. Le Romancer M, Treilleux I, Leconte N, Robin-Lespinasse Y, Sentis S, Bouchekioua-Bouzaghou K, Goddard S, Gobert-Gosse S, Corbo L. Regulation of estrogen rapid signaling through arginine methylation by PRMT1. Mol Cell 2008; 31: 212-221 [PMID: 18657504 DOI: 10.1016/j.molcel.2008.05.025]
36. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004; 11: 643-658 [PMID: 15613444 DOI: 10.1677/erc.1.00776]
37. Loi S, Sotiriou C, Haibe-Kains B, Lallemand F, Conus NM, Piccart MJ, Speed TP, McArthur GA. Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer. BMC Med Genomics 2009; 2: 37 [PMID: 19552798 DOI: 10.1186/1755-8794-2-37]
38. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S, Carroll JS. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 2008; 456: 663-666 [PMID: 19005469 DOI: 10.1038/nature07483]
39. Hutcheson IR, Knowlden JM, Madden TA, Barrow D, Gee JM, Wakeling AE, Nicholson RI. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifenresistant MCF-7 cells. Breast Cancer Res Treat 2003; 81: 81-93 [PMID: 14531500 DOI: 10.1023/A: ]
40. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003; 144: 1032-1044 [PMID: 12586780 DOI: 10.1210/en.2002-220620]
41. Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J, Harris J, Spector NL. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA 2006; 103: 7795-7800 [PMID: 16682622 DOI: 10.1073/pnas.0602468103]
42. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Révil C, Jones A. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009; 27: 5529-5537 [PMID: 19786670 DOI: 10.1200/JCO.2008.20.6847]
43. Schwartzberg LS, Franco SX, Florance A, ORourke L, Maltzman J, Johnston S. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 2010; 15: 122-129 [PMID: 20156908 DOI: 10.1634/theoncologist.2009-0240]
44. Miller DL, el-Ashry D, Cheville AL, Liu Y, McLeskey SW, Kern FG. Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression. Cell Growth Differ 1994; 5: 1263-1274 [PMID: 7696175]
45. Fedele P, Calvani N, Marino A, Orlando L, Schiavone P, Quaranta A, Cinieri S. Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going? Crit Rev Oncol Hematol 2012; 84: 243-251 [PMID: 22494933 DOI: 10.1016/j.critrevonc .2012.03.004]
46. Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F, Eppenberger U. Potential prognostic value of mitogen-Activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer 2000; 89: 384-388 [PMID: 10956414]
47. Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill PJ. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 2010; 16: 1904-1914 [PMID: 20215537 DOI: 10.1158/1078-0432.CCR-09-2282]
48. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008; 68: 826-833 [PMID: 18245484 DOI: 10.1158/0008-5472.CAN-07-2707]
49. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-Talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004; 96: 926-935 [PMID: 15199112 DOI: 10.1093/jnci/djh166]
50. Leary AF, Drury S, Detre S, Pancholi S, Lykkesfeldt AE, Martin LA, Dowsett M, Johnston SR. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res 2010; 16: 1486-1497 [PMID: 20179226 DOI: 10.1158/1078-0432.CCR-09-1764]
51. Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, ORourke L, Oliva C, Stein S, Pegram M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27: 5538-5546 [PMID: 19786658 DOI: 10.1200/JCO.2009.23.3734]
52. Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK, Rimm DL, Magill P, Sellers M. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: A randomized phase II study. Clin Cancer Res 2011; 17: 1147-1159 [PMID: 21220480 DOI: 10.1158/1078-0432.CCR-10-1869]
53. Polychronis A, Sinnett HD, Hadjiminas D, Singhal H, Mansi JL, Shivapatham D, Shousha S, Jiang J, Peston D, Barrett N, Vigushin D, Morrison K, Beresford E, Ali S, Slade MJ, Coombes RC. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: A double-blind placebo-controlled phase II randomised trial. Lancet Oncol 2005; 6: 383-391 [PMID: 15925816 DOI: 10.1016/S1470-2045(05)70176-5]
54. Smith IE, Walsh G, Skene A, Llombart A, Mayordomo JI, Detre S, Salter J, Clark E, Magill P, Dowsett M. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 2007; 25: 3816-3822 [PMID: 17679728 DOI: 10.1200/JCO.2006.09.6578]
55. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8: 627-644 [PMID: 19644473 DOI: 10.1038/nrd2926]
56. Tran B, Bedard PL. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res 2011; 13: 221 [PMID: 22217398 DOI: 10.1186/bcr2904]
57. Trotman LC, Pandolfi PP. PTEN and p53: who will get the upper hand? Cancer Cell 2003; 3: 97-99 [PMID: 12620402 DOI: 10.1016/S1535-6108(03)00022-9]
58. Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 2010; 29: 4018-4032 [PMID: 20473330 DOI: 10.1038/onc.2010.154]
59. DeGraffenried LA, Fulcher L, Friedrichs WE, Grönwald V, Ray RB, Hidalgo M. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol 2004; 15: 1510-1516 [PMID: 15367412 DOI: 10.1093/annonc/mdh388]
60. Ghayad SE, Bieche I, Vendrell JA, Keime C, Lidereau R, Dumontet C, Cohen PA. mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci 2008; 99: 1992-2003 [PMID: 19016759 DOI: 10.1111/j.1349-7006.2008.00955.x]
61. Treeck O, Wackwitz B, Haus U, Ortmann O. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol Oncol 2006; 102: 292-299 [PMID: 16443261 DOI: 10.1016/j.ygyno.2005.12.019]
62. Sadler TM, Gavriil M, Annable T, Frost P, Greenberger LM, Zhang Y. Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus. Endocr Relat Cancer 2006; 13: 863-873 [PMID: 16954435 DOI: 10.1677/erc.1.01170]
63. Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A, DeGraffenried LA. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007; 18: 1323-1328 [PMID: 17693645 DOI: 10.1093/annonc/mdm170]
64. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009; 27: 2630-2637 [PMID: 19380449 DOI: 10.1200/JCO.2008.18.8391]
65. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-529 [PMID: 22149876 DOI: 10.1056/NEJMoa1109653]
66. Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. J Clin Oncol 2012; 30: 2718-2724 [PMID: 22565002 DOI: 10.1200/JCO.2011.39.0708]
67. Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincat S, Chow L, Sun Y, Neskovic-Konstantinovic Z, Guimaraes RC, Fumoleau P, Chan A, Hachemi S, Strahs A, Cincotta M, Berkenblit A, Krygowski M, Kang LL, Moore L, Hayes DF. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2013; 31: 195-202 [PMID: 23233719 DOI: 10.1200/JCO.2011.38.3331]
68. Sahebjam S, Siu LL, Razak AA. The utility of hedgehog signaling pathway inhibition for cancer. Oncologist 2012; 17: 1090-1099 [PMID: 22851551 DOI: 10.1634/theoncologist. 2011-0450]
69. Takebe N, Hunsberger S, Yang SX. Expression of Gli1 in the hedgehog signaling pathway and breast cancer recurrence. Chin J Cancer Res 2012; 24: 257-258 [PMID: 23358885]
70. Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 2006; 24: 3019-3025 [PMID: 16754938 DOI: 10.1200/JCO.2005.04.3034]
71. Ramaswamy B, Lu Y, Teng KY, Nuovo G, Li X, Shapiro CL, Majumder S. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Res 2012; 72: 5048-5059 [PMID: 22875023 DOI: 10.1158/0008-5472.CAN-12-1248]
72. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-928 [PMID: 19029956 DOI: 10.1038/nrc2536]
73. Shimizu C, Hasegawa T, Tani Y, Takahashi F, Takeuchi M, Watanabe T, Ando M, Katsumata N, Fujiwara Y. Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. Hum Pathol 2004; 35: 1537-1542 [PMID: 15619214 DOI: 10.1016/j.humpath.2004.09.005]
74. Lukas J, Bartkova J, Bartek J. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol 1996; 16: 6917-6925 [PMID: 8943347]
75. Kaufman JF, H Bourgeois, H Kennecke. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG With Exemestane (E) or Fulvestrant (F) in Postmenopausal Women With Hormone-Receptor Positive (HR ) Metastatic (M) or Locally Advanced (LA) Breast Cancer (BC). Cancer Res 2010; 70: S1-4
76. Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P, Tabernero J. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol 2014; 25: 552-563 [PMID: 24265351 DOI: 10.1093/annonc/mdt419]
77. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10: 116-129 [PMID: 20094046 DOI: 10.1038/nrc2780]
78. Heinzle C, Sutterlöty H, Grusch M, Grasl-Kraupp B, Berger W, Marian B. Targeting fibroblast-growth-factor-receptordependent signaling for cancer therapy. Expert Opin Ther Targets 2011; 15: 829-846 [PMID: 21375471 DOI: 10.1517/147 28222.2011.566217]
79. Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J 2011; 437: 199-213 [PMID: 21711248 DOI: 10.1042/BJ20101603]
80. Hynes NE, Dey JH. Potential for targeting the fibroblast growth factor receptors in breast cancer. Cancer Res 2010; 70: 5199-5202 [PMID: 20570901 DOI: 10.1158/0008-5472. CAN-10-0918]
81. André F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S, Shi M, Zhang Y, Kay A, Porta DG, Yovine A, Baselga J. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res 2013; 19: 3693-3702 [PMID: 23658459 DOI: 10.1158/1078-0432.CCR-13-0190]
82. Mandlekar S, Kong AN. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001; 6: 469-477 [PMID: 11595837]
83. Riggins RB, Bouton AH, Liu MC, Clarke R. Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitam Horm 2005; 71: 201-237 [PMID: 16112269 DOI: 10.1016/S0083-6729(05)71007-4]
84. Wang Y, Dean JL, Millar EK, Tran TH, McNeil CM, Burd CJ, Henshall SM, Utama FE, Witkiewicz A, Rui H, Sutherland RL, Knudsen KE, Knudsen ES. Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Res 2008; 68: 5628-5638 [PMID: 18632615 DOI: 10.1158/0008-5472.CAN-07-3170]
85. Thangavel C, Dean JL, Ertel A, Knudsen KE, Aldaz CM, Witkiewicz AK, Clarke R, Knudsen ES. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer 2011; 18: 333-345 [PMID: 21367843 DOI: 10.1530/ERC-10-0262]
86. Finn RS, Crown JP, Lang I. Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER /HER2-Advanced breast cancer (BC). Cancer Res 2012: 24 Suppl: Abstract nr S1-6
87. Finn RS, Dieras V, Gelmon KA. A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole vs placebo plus letrozole for the treatment of postmenopausal women with ER( ), HER2(-) breast cancer who have not received any prior systemic anticancer treatment for advanced disease. J Clin Oncol 2013; 14
88. Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ, de Cremoux P, Stenvang J, Lykkesfeldt AE. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 2009; 114: 263-275 [PMID: 18409071 DOI: 10.1007/s10549-008-0011-8]
89. Lustberg MB, Ramaswamy B. Epigenetic Therapy in Breast Cancer. Curr Breast Cancer Rep 2011; 3: 34-43 [PMID: 23097683 DOI: 10.1007/s12609-010-0034-0]
90. Ferguson AT, Lapidus RG, Baylin SB, Davidson NE. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 1995; 55: 2279-2283 [PMID: 7538900]
91. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)-Alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-Alpha-negative breast cancer cells. Cancer Res 2001; 61: 7025-7029 [PMID: 11585728]
92. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 2011; 104: 1828-1835 [PMID: 21559012 DOI: 10.1038/bjc.2011.156]
93. Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ, Trepel JB. Randomized phase II, double-blind, placebocontrolled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol 2013; 31: 2128-2135 [PMID: 23650416 DOI: 10.1200/JCO.2012.43.7251]
94. Lu Y, Roy S, Nuovo G, Ramaswamy B, Miller T, Shapiro C, Jacob ST, Majumder S. Anti-microRNA-222 (anti-miR-222) and-181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem 2011; 286: 42292-42302 [PMID: 22009755 DOI: 10.1074/jbc.M111.270926]